Teva Pharmaceutical Industries (TEVA) Long-Term Investments (2009 - 2012)
Teva Pharmaceutical Industries' (TEVA) quarterly Long-Term Investments came in at $1.2 billion in Q3 2012, up 105.09% YoY from $589.0 million in Q4 2011, and up 8.34% on a QoQ basis from $1.1 billion in Q2 2012.
Teva Pharmaceutical Industries (TEVA) Long-Term Investments (2009 - 2012) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 4 years of Long-Term Investments data on file, last reported at $1.2 billion in Q3 2012.
- Quarterly Long-Term Investments rose 105.09% year-over-year to $1.2 billion in Q3 2012, while the trailing twelve-month figure through Sep 2012 was $1.2 billion (up 105.09% YoY) and the FY2011 annual result came in at $991.0 million, up 56.8% from the prior year.
- Long-Term Investments improved to $1.2 billion in Q3 2012, from $1.1 billion in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $1.2 billion in Q3 2012 to a low of $406.0 million in Q1 2009.
- A 4-year average of $717.1 million and a median of $650.0 million in 2011 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2011 — Long-Term Investments retreated 13.38% — and 2012, when it jumped 105.09%.
- Tracing TEVA's Long-Term Investments over 4 years: stood at $534.0 million in 2009, then increased by 18.35% to $632.0 million in 2010, then soared by 56.8% to $991.0 million in 2011, then rose by 21.9% to $1.2 billion in 2012.
- The last three Long-Term Investments figures came in at $1.2 billion (Q3 2012), $1.1 billion (Q2 2012), and $1.0 billion (Q1 2012), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | 92.58 Mn |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 63.23 Mn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 1.14 Bn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 149.10 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 60.00 Mn |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | 35.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2012 | 1.21 Bn |
| Jun 30, 2012 | 1.12 Bn |
| Mar 31, 2012 | 1.04 Bn |
| Dec 31, 2011 | 991.00 Mn |
| Sep 30, 2011 | 589.00 Mn |
| Jun 30, 2011 | 650.00 Mn |
| Mar 31, 2011 | 671.00 Mn |
| Dec 31, 2010 | 632.00 Mn |
| Sep 30, 2010 | 680.00 Mn |
| Jun 30, 2010 | 628.00 Mn |
| Mar 31, 2010 | 665.00 Mn |
| Dec 31, 2009 | 534.00 Mn |
| Sep 30, 2009 | 484.00 Mn |
| Jun 30, 2009 | 459.00 Mn |
| Mar 31, 2009 | 406.00 Mn |